reglab/statecodes huggingface dataset:
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2081 - ELECTRONIC PRESCRIPTION MONITORING PROGRAM - LONG TERM CARE › Section 2081.70 - Designated Medications

Current through Register Vol. 48, No. 28, July 12, 2024
For tracking purposes, the Department, by recommendation of the
				PMPAC may designate and list drugs, other substances or immediate precursors
				as:
a) A Schedule I, if the Department
			 finds that:
1)
the substance has high
			 potential for abuse; and
2)
the substance has no currently
			 accepted medical use in treatment in the United States or lacks accepted safety
			 for use in treatment under medical supervision
[720 ILCS
			 570/203 ].
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2081 - ELECTRONIC PRESCRIPTION MONITORING PROGRAM - LONG TERM CARE › Section 2081.80 - Mid-Level Practitioners Prescriptive Authority Reporting

Current through Register Vol. 48, No. 28, July 12, 2024
In order to prevent erroneous association of prescriptions and
				remain compliant with the PMP, any supervising or collaborating physician who
				has delegated prescriptive authority to a mid-level practitioner is required to
				log in and fill out the electronic form on the PMP website (www.ilpmp.org)
				detailing what prescriptive authority he or she has delegated (see Section
				318(k) of the Act). It is incumbent upon the collaborating or supervising
				physician to keep this record up to date. The form will require, but not be
				limited to, the following data fields:
a) Mid-level practitioner's information
			 necessary for the electronic PMP form:
1)
			 Name (First, MI, Last);
2) DEA
			 number;
3) Profession;
			 and
4) Mid-Level Practitioner's
			 Professional License Numbers.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2085 - RESEARCH › Section 2085.10 - Definitions

Current through Register Vol. 48, No. 28, July 12, 2024
As used in this Part, unless the context otherwise
				requires:
"Delta-9-THC" means delta-9-tetrahydrocannabinol capsules
				issued by the National Cancer Institute for the treatment of cancer
				chemotherapy patients.
"DEA" means the Drug Enforcement Administration of the United
				State Department of Justice or its successor agency.
"Guidelines" means the "Group C Guidelines for the Use of
				Delta-9-tetrahydrocannabinol NSC 134454 for Nausea and Vomiting Induced by
				Antineoplastic Chemotherapy", Protocol 180-12, September, 1080, issued by the
				National Cancer Institute".
"Mechanism" means the "Mechanism of Drug Distribution for
				Delta-9-Tetrahydrocannabinol (NSC-134454)" issued by the National Cancer
				Institute.
"NCI" means the National Cancer Institute or its successor
				agency.
"Research Order Forms" means the duplicate order forms supplied
				by the Department to authorized hospital pharmacies for prescribing delta-9-THC
				to cancer chemotherapy patients and entitled "Research Order for delta-9-THC
				Medication".
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2085 - RESEARCH › Section 2085.15 - Eligibility

Current through Register Vol. 48, No. 28, July 12, 2024
Hospitals and their pharmacies which have been registered and
				approved by the NCI and the DEA to use delta-9-THC in the treatment of cancer
				chemotherapy patients may be authorized by the Department to use delta-9-THC
				for such purposes in Illinois. The authorization will be granted upon
				satisfactory completion of the Department authorization
				procedure.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2085 - RESEARCH › Section 2085.20 - Authorization Procedure

Current through Register Vol. 48, No. 28, July 12, 2024
a)
			 Hospital
1) Submit copies of Federal
			 registration forms to the Department with a cover letter that:
A) identifies the institution,
B) indicates agreement to comply with Federal
			 and State regulations and protocol concerning the use of THC, and
C) agreement to promptly notify the
			 Department in writing of any physician enrolled or disenrolled in the
			 research.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2085 - RESEARCH › Section 2085.25 - Terms and Conditions of Authorization

Current through Register Vol. 48, No. 28, July 12, 2024
a) The hospital pharmacy upon receipt of
			 written authorization by the Department may dispense delta-9-THC to cancer
			 chemotherapy patients in conformity with this Part, all requirements imposed by
			 the NCI as set forth in the Mechanisms and the Guidelines and all applicable
			 regulations of the DEA. Failure to adhere to such applicable requirements may
			 result in the suspension or revocation of Department authorization.
b) In determining whether to approve an
			 application, the Department will consider the following factors:
1) Whether the application contains false or
			 fraudulent information or material;
2) Whether the applicant maintains current
			 Federal and State licenses as required by law;
3) Whether the applicant has established and
			 maintains adequate security of its drug stocks and in the handling of such
			 stocks;
4) Whether the applicant
			 has agreed to comply with the procedures imposed by NCI as set forth under the
			 Mechanism and the Guidelines and other applicable protocols; and
5) Whether the applicant maintains and
			 adheres to acceptable professional standards in the provision of medical and/or
			 hospital services.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2085 - RESEARCH › Section 2085.30 - Informed Consent

Current through Register Vol. 48, No. 28, July 12, 2024
Persons authorized to use delta-9-THC in the treatment of
				cancer chemotherapy patients shall insure that prior to the dispensing of any
				delta-9-THC medication, informed consent has been obtained from the patient.
				Such informed consent shall be in writing and meet all requirements imposed by
				the NCI and 77 Ill. Adm. Code 2055.480(b) and (f). An institutional informed
				consent form may be used. The execution of the informed consent form issued by
				the NCI as part of the Guidelines by the patient shall be deemed compliance
				with the requirements of this Subsection. The original executed informed
				consent form shall remain in the patient's primary record file. In the case of
				a minor, the parent or legal guardian must execute the informed consent
				form.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2085 - RESEARCH › Section 2085.35 - Research Order Blanks for Dispensing Delta-9-THC Capsules

Current through Register Vol. 48, No. 28, July 12, 2024
a) The hospital pharmacy may dispense
			 delta-9-THC upon presentation of a "Research Order for
			 Delta-9-Tetrahydrocannabinol Medication" signed by a physician who:
1) Has a current DEA registration and
			 Illinois Controlled Substances number;
2) Has registered with the pharmacy by filing
			 a Form FDA-1573 and has been approved by the participating pharmacy, the
			 Department, the Illinois Department of Law Enforcement, and NCI;
3) Affirms that the patient consent form has
			 been signed by the patient;
4)
			 Limits the use of the drug to the indications outlined in the
			 Guidelines;
5) Will report adverse
			 drug reactions on Form FD 1639-a to the Investigational Drug Branch of the NCI
			 and the Department; and
6) Has met
			 all other requirements imposed by the NCI as set forth in the
			 Mechanism.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2085 - RESEARCH › Section 2085.40 - Labeling Requirements

Current through Register Vol. 48, No. 28, July 12, 2024
a)
			 Medication for Outpatient Use
The hospital pharmacy shall affix to the package or container
				of delta-9-THC Medication a label showing date of filling, the hospital
				pharmacy name, address and telephone number, the pharmacy DEA number, the
				serial number of the research order, the name of the patient, the name of the
				prescribing physician, the directions for use, the period covered by the
				research order, the name, strength and quantity of medication, the pharmacist's
				initials, and the following cautionary statements: The medication is
				non-refillable, the patient is to return unused portions of the medication, and
				Federal and State law prohibits the transfer or use of the medication by any
				person other than the person for whom it is prescribed. A sample label is
				attached as Exhibit D.
b)
			 Medication for Inpatient Use
Delta-9-THC Medication prescribed and dispensed for a patient
				who is institutionalized may be exempt from the provisions of subparagraph 1
				above in accordance with
				21 CFR
				1306.14(b).
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2085 - RESEARCH › Section 2085.45 - Packaging Requirements

Current through Register Vol. 48, No. 28, July 12, 2024
All delta-9-THC medication dispensed pursuant to the
				authorization granted under this Part shall be in containers having child-proof
				caps in conformance with the requirements of 16 CFR 1700, Annex A of this
				Part.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2085 - RESEARCH › Section 2085.50 - Confidentiality of Cancer Chemotherapy Patients Receiving delta-9-THC Medication

Current through Register Vol. 48, No. 28, July 12, 2024
The provisions of 77 Ill. Adm. Code 2055.480(g),
				Confidentiality of Research Subjects, are applicable to cancer chemotherapy
				patients receiving delta-9-THC medication as part of a program approved by the
				Department under this Part.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2085 - RESEARCH › Section 2085.55 - Reports and Recordkeeping

Current through Register Vol. 48, No. 28, July 12, 2024
a)
			 Copies of all reports and forms required under the Mechanism and the Guidelines
			 to be submitted to the NCI and DEA shall be submitted to the
			 Department.
b) Research orders
			 filled by the hospital pharmacy shall be kept on pharmacy premises separate and
			 apart from other pharmacy documents and shall be filed by date of filling. Such
			 Research Orders shall be available to Department personnel for inspection and
			 audit.
c) The original and one copy
			 of the Research Order for delta-9-THC Medication shall be delivered to the
			 hospital pharmacy. The original Research Order Form for delta-9-THC Medication
			 shall be retained by the hospital pharmacy and by the
			 15th of the month following the month in which the
			 Research Order Form was filled, the duplicate shall be returned to the
			 Department. The duplicate copy shall not contain any patient or recipient
			 identifying information. The pharmacy shall retain their copies of the orders
			 for the same period as required for controlled substances pursuant to the
			 Illinois Pharmacy Act (Ill. Rev. Stat. 1981, ch. 111, par. 4030).
d) Any unused medication shall be returned to
			 the distributing pharmacy upon completion of the Research Order expiration
			 date. Any unused amount of THC shall be recorded on the form which issued the
			 THC to the patient. It may be redispensed to the same patient pursuant to a new
			 Research Order. Such redistribution period shall not extend beyond the lot
			 expiration date.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2085 - RESEARCH › Section 2085.60 - Audits and Inspections

Current through Register Vol. 48, No. 28, July 12, 2024
Department staff shall be permitted access during normal
				working hours to all records and areas for the purpose of conducting audits and
				inspections to determine compliance with applicable laws, regulations and
				requirements of the NCI governing the use of delta-9-THC in the treatment of
				cancer chemotherapy patients.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2085 - RESEARCH › Section 2085.65 - Security

Current through Register Vol. 48, No. 28, July 12, 2024
a) All delta-9-THC
			 shall be stored within the pharmacy storage area in compliance with the
			 provisions of Title 21 of the Code of Federal Regulations, Part 1301.75(a). The
			 minimum security required thereunder is a securely locked, substantially
			 constructed cabinet.
b) Research
			 Order forms shall be accounted for, maintained and secured to prevent
			 unauthorized access and use.
c) All
			 medications governed by this Part require the same physical security as
			 demanded by the rules and regulations governing Schedule II controlled
			 substances.
d) Contaminated
			 medication shall be returned for disposal as authorized by the
			 Department.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2085 - RESEARCH › Exhibit A - DAS Form 229-1

Current through Register Vol. 48, No. 28, July 12, 2024
(Hospital Letter Head)
Chief of Licensing
Department of Alcoholism and Substance Abuse
300 N. State Street-Suite 1500
Chicago, Illinois 60610
Sir:
We hereby apply for authorization from the Department to
				conduct research with Delta-9-Tetrahydrocannabinol. Enclosed is a copy of Form
				DEA-225 "New Application for Registration under Controlled Substances Act of
				1970", and a copy of our application to the National Cancer Institute (NCI) to
				participate in their research study. The research will be conducted under the
				NCI approved Protocol I 80-12 "Group C Guidelines for the Use of
				Delta-9-Tetrahydrocanncbinol NSC 134454 for Nausea and Vomiting Induced by
				Antineoplastic Chemotherapy". Applications for the individual physicians who
				have been approved by this hospital to issue the research order for medication
				are also enclosed.
We agree to comply with all pertinent Federal and State
				regulations and protocols concerning the use of THC. We will notify the
				Department in writing of any new physician enrolled, or any who no longer wish
				to participate in the research study.
Sincerely,
Director of Pharmacy
				Services
Hospital
				Administrator
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2085 - RESEARCH › Exhibit B - DASA Form 229-2

Current through Register Vol. 48, No. 28, July 12, 2024
(Physician Letter Head)
Chief of Licensing
Illinois Department of Alcoholism and Substance Abuse
300 N. State Street-Suite 1500
Chicago, Illinois 60610
Sir:
I hereby apply for authorization from the Department to conduct
				research with Delta-9-Tetrahydrocannabinol under the National Cancer Institute
				(NCI) approved Protocol I 80-12 "Group C Guidelines for the Use of
				Delta-9-Tetrahydrocannabinol NSC 134454 for Nausea and Vomiting Induced by
				Antineoplastic Chemotherapy". Enclosed is a copy of FDA Form 1573 "Statement of
				Investigator" which has been submitted to NCI.
I agree to limit drug usage to the indications outlined in
				Group C Guidelines, to ensure that each patient has completed an informed
				consent form, to report adverse drug reactions immediately to the Department,
				as well as NCI, and to comply with Federal and State regulations concerning the
				use of THC. I will notify the Department if I no longer choose to participate
				in the research study.
Sincerely,
M.D.
___________________________________________________
Physician's Name
DEA # ________________
Illinois Controlled Substance #
				_________________________
Hospital Name and Address:
The above named physician has met the professional
				qualifications and possesses the requisite professional experience in Cancer
				Chemotherapy to participate in NCI Protocol I 80-12. This physician is approved
				to practice this therapy, under the NCI Protocol I 80-12, at __________
				Hospital.
Director of Pharmacy
				Services
Hospital
				Administrator
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2085 - RESEARCH › Exhibit C - Special Instructions overing Research Medication Order Forms for Delta-9-Tetrahydrocannabinol

Current through Register Vol. 48, No. 28, July 12, 2024
The Department will provide blanks of serially numbered
				Official Medication Order Forms to authorized registrant hospital pharmacies.
				The forms shall be in the following format:
A. HEADING SECTION
Each order form heading shall contain the following
				information.
1. In the upper left hand
			 corner shall be printed "State of Illinois Department of Alcoholism and
			 Substance Abuse" with the agency telephone number.
2. In the upper middle portion, the name,
			 address and zip code of the hospital pharmacy shall be imprinted between the
			 prepunched holes. Below this, the DEA registration number for the hospital
			 pharmacy should appear. The individual registrant hospital pharmacy is
			 responsible to accomplish that printing, which may be typewritten or
			 stamped.
3. In the upper right hand
			 corner, the words "Order Serial Number" shall be imprinted. This order serial
			 number will serve as a control number and be placed on the hospital pharmacy's
			 dispensing label.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2090 - SUBACUTE ALCOHOLISM AND SUBSTANCE ABUSE TREATMENT SERVICES › Section 2090.10 - Purpose

Current through Register Vol. 48, No. 28, July 12, 2024
a) The requirements
			 set forth in this Part establish criteria for participation by subacute
			 alcoholism and other drug abuse treatment programs in the Illinois Medical
			 Assistance Program operated by the Illinois Department of Public Aid
			 (IDPA).
b) The Department of Human
			 Services (the Department), acting on behalf of IDPA shall certify the
			 eligibility of applicants for participation who meet these
			 requirements.
c) These requirements
			 are in addition to licensure standards established in 77 Ill. Adm. Code 250
			 (Hospital Licensing Requirements) and 77 Ill. Adm. Code 2060 (Alcoholism and
			 Substance Abuse Treatment and Intervention Licenses), and are for the purpose
			 of assuring that Medicaid recipients shall receive quality services in
			 accordance with 42 CFR 440 and 456.
d) These requirements shall be used by the
			 Department for certification, recertification, and periodic inspection of
			 providers participating in the Medical Assistance Program.
e) In addition to the duties of the
			 Department above, the Department shall also allocate monies within its budget,
			 which shall be for the purpose of reimbursement to certified providers for
			 Medicaid eligible services, as described in this Part, on behalf of IDPA. The
			 Department shall, together with and by agreement with IDPA, provide for such
			 reimbursement out of such funds.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2090 - SUBACUTE ALCOHOLISM AND SUBSTANCE ABUSE TREATMENT SERVICES › Section 2090.20 - Definitions

Current through Register Vol. 48, No. 28, July 12, 2024
The following definitions shall apply to this Part:
"Adolescent": A person who is at least twelve years of age and
				under eighteen years of age.
"Benefit Year": The State fiscal year.
"Client": Any person who is eligible to receive services under
				one of the following categories: Aged, Blind, and Disabled (AABD); Temporary
				Assistance for Needy Families (TANF); Medical Assistance, No Grant (MANG);
				Refugee Repatriate Program (RRP); Title XIX eligible Department of Children and
				Family Services (DCFS) wards; and persons under the age of eighteen who would
				qualify for TANF but do not qualify as dependent children pursuant to 89 Ill.
				Adm. Code
				140.7.
"Department": The Illinois Department of Human Services.
"Physician": A person who is licensed to practice medicine in
				all its branches under the Medical Practice Act of 1987 [225 ILCS 60 ].
"Professional Staff": Any person who provides clinical services
				as defined in 77 Ill. Adm. Code 2060 and who meets the requirements for
				professional staff as specified in 77 Ill. Adm. Code
				2060.309.
				Professional staff may also be a person determined to be appropriate to deliver
				the clinical services provided, in accordance with 77 Ill. Adm. Code 250,
				Subpart W.
"Provider": Any public or private agency, organization, or
				institution, or unit of State or local government or other legal entity
				licensed to deliver alcoholism or other drug abuse services according to the
				requirements specified in 77 Ill. Adm. Code 2060 and enrolled to provide
				treatment services under the Illinois Medical Assistance Program.
"Psychiatrist": A person licensed to practice medicine in all
				its branches under the Medical Practice Act of 1987 [225 ILCS 60] and who meets
				the requirements of Section 1-121 of the Mental Health and Developmental
				Disabilities Code [405 ILCS 5/1-121 ].
"Subacute": The level of care necessary to effectively treat an
				alcohol and/or other drug abuser's dependency on a chemical without the more
				intensive measures designed to treat primary medical conditions in an acute
				care setting (e.g., inpatient hospitalization). Subacute care may be delivered
				in a facility licensed under the rules for Alcoholism and Substance Abuse
				Treatment and Intervention Licenses (77 Ill. Adm. Code 2060) or in a hospital,
				either of which is certified according to Section
				2090.30
				for purposes of Medicaid reimbursed alcoholism and/or other drug abuse
				services.
"Treatment Plan": An individually written plan for a client
				which identifies the treatment goals and objectives based upon a clinical
				assessment of the client's individual problems, needs, strengths and
				weaknesses.
"Under the direction of a physician": Treatment services
				provided under the direct supervision of a physician who is on staff and
				continuously directs the provision of care.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2090 - SUBACUTE ALCOHOLISM AND SUBSTANCE ABUSE TREATMENT SERVICES › Section 2090.30 - Medicaid Certification/Enrollment/Recertification

Current through Register Vol. 48, No. 28, July 12, 2024
a) Providers may be certified and recertified
			 by the Department as set forth herein and may enroll for participation in the
			 Illinois Medical Assistance Program as provided in 89 Ill. Adm. Code
			 148.340(d).
			 Application for Medicaid certification and enrollment for alcoholism and other
			 drug abuse treatment service providers may be made by providers who are:
1) Currently licensed by the Department under
			 the provisions of 77 Ill. Adm. Code 2060 for alcoholism and other drug abuse
			 treatment services described in 77 Ill. Adm. Code 2060.
2) Currently licensed by the Illinois
			 Department of Public Health as a hospital pursuant to 77 Ill. Adm. Code 250 for
			 the treatment services described in 77 Ill. Adm. Code 250.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2090 - SUBACUTE ALCOHOLISM AND SUBSTANCE ABUSE TREATMENT SERVICES › Section 2090.35 - General Requirements

Current through Register Vol. 48, No. 28, July 12, 2024
a) To be
			 reimbursable, treatment services shall be provided in compliance with all
			 provisions specified in 77 Ill. Adm. Code 2060. Specifically, physician and
			 professional staff involvement in treatment services shall be in compliance
			 with 77 Ill. Adm. Code
			 2060.417,
			 2060.419,
			 2060.421,
			 2060.423
			 and
			 2060.425.
			 The provider shall only bill for services that are reimbursable.
b) The provider shall submit Medicaid claims
			 as soon after the service date as is reasonable unless there is good cause for
			 later submission. In any event, all claims for services (both initial and
			 previously rejected) must be submitted to the State on a timely enough basis to
			 be paid within 12 months from the date of service. If such claims are not
			 submitted within this time frame, the provider may request an exception from
			 the Department and IDPA to allow these claims to be processed. Exceptions will
			 only be granted if it is determined that the delay in submission was due to
			 Department or IDPA processing errors.
c) Information Collection
1) The provider shall report, on a monthly
			 basis, demographic and service system data using the Department's Automated
			 Reporting and Tracking System (DARTS), in the manner and data format prescribed
			 by the Department. The data collected shall be for the purpose of assessing
			 individual client performance and for planning for future service development.
			 Information to be reported by the provider, for each individual served by a
			 program certified under Section
			 2090.90 of this Part,
			 shall include but is not limited to the following:
A) Name, date of birth, gender, race and
			 national origin, family size, income level, marital status, residential
			 address, employment, education and referral source.
B) Special population designation, such as
			 Medicaid eligible clients, women with dependent children, intravenous drug
			 users (IVDUs), DCFS clients, DHS clients, and criminal justice
			 clients.
C) Drug/alcohol problem
			 areas treated, characterized by drugs of use, frequency of use, and medical
			 diagnosis.
D) Closing date
			 information, such as the reason for discharging the client from the
			 program.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2090 - SUBACUTE ALCOHOLISM AND SUBSTANCE ABUSE TREATMENT SERVICES › Section 2090.40 - Reimbursable Services

Current through Register Vol. 48, No. 28, July 12, 2024
a) Level
			 I: (formerly Outpatient Services)
1)
			 Definition
The provision of treatment services as defined in 77 Ill. Adm.
				Code
				2060.401(b).
2) Reimbursement
Level I treatment services delivered to clients are
				Medicaid-reimbursable via the prospective rates in effect as of the date of
				service (89 Ill. Adm. Code
				148.370
				). Medicaid claims are submitted to the Department and shall meet the
				requirements of IDPA rules for alcoholism and substance abuse treatment
				programs (89 Ill. Adm. Code
				148.340
				through 148.370). The billable unit of service is a client hour defined as
				face-to-face counseling with a diagnosed client in an individual or group
				setting. Reimbursement shall occur by a fee-for-service mechanism, using one
				client hour as the base unit of service, billable to the nearest quarter-hour.
				No more than 25 hours may be reimbursed for an eligible adult client per
				benefit year.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2090 - SUBACUTE ALCOHOLISM AND SUBSTANCE ABUSE TREATMENT SERVICES › Section 2090.50 - Quality Improvement

Current through Register Vol. 48, No. 28, July 12, 2024
Each provider shall have and adhere to a quality improvement
				plan developed in compliance with the provisions in 77 Ill. Adm. Code
				2060.315.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2090 - SUBACUTE ALCOHOLISM AND SUBSTANCE ABUSE TREATMENT SERVICES › Section 2090.70 - Rate Setting

Current through Register Vol. 48, No. 28, July 12, 2024
a) The amount
			 approved for payment for alcoholism and other drug abuse treatment is based on
			 the category and amount of services required by and actually delivered to a
			 client. The amount is determined in accordance with prospective rates developed
			 by the Department and adopted by the Department of Public Aid. The adopted rate
			 shall not exceed the charges to the general public.
b) Rates are generated through the
			 application of formal methodologies specific to each reimbursable service as
			 specified in Section
			 2090.40 of
			 this Part.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2090 - SUBACUTE ALCOHOLISM AND SUBSTANCE ABUSE TREATMENT SERVICES › Section 2090.80 - Rate Appeals

Current through Register Vol. 48, No. 28, July 12, 2024
a) Providers
			 may appeal their rates in writing within 30 calendar days of the postmark date
			 of the rate notice.
b) Appeals
			 shall be submitted to the Department.
c) The Department shall determine whether a
			 reason for the appeal exists pursuant to subsection (d) of this Section and
			 that the written appeal contains all elements required in subsection (e) of
			 this Section. Further clarification of the information submitted may be
			 requested of the provider.
d) Rate
			 appeals may be considered for the following reasons:
1) Mechanical or clerical errors committed by
			 the provider in reporting historical expenses used in the calculation of
			 allowable costs.
2) Mechanical or
			 clerical errors committed by the Department in auditing historical expenses as
			 reported and/or in calculating reimbursement rates.
3) The Department and the provider have
			 entered into a written agreement to amend, alter, or modify substantive
			 programmatic or management procedures attendant to the delivery of services,
			 which have a substantial impact upon the costs of service delivery.
4) The Department has amended the licensed
			 capacity of a facility or treatment service.
5) The Department requires substantial
			 treatment service changes as a result of mandated licensure
			 requirements.
6) The Department
			 requires substantial changes in physical plant as a result of mandated
			 licensure requirements. In such instances, the provider must submit a plan of
			 corrections for capital improvements approved by the licensing authority, along
			 with the required cost information.
7) State and/or federal regulatory
			 requirements have generated a substantial increase in allowable
			 costs.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2090 - SUBACUTE ALCOHOLISM AND SUBSTANCE ABUSE TREATMENT SERVICES › Section 2090.90 - Inspections

Current through Register Vol. 48, No. 28, July 12, 2024
a) The Department
			 shall conduct inspections of applicants for program certification or
			 recertification and of certified programs to enforce compliance with this Part.
			 Department inspections may be conducted as part of the
			 certification/recertification application process, on a random basis to survey
			 compliance with this Part, or in response to complaints, if the complaint sets
			 forth charges that constitute grounds for sanction pursuant to Section
			 2090.100.
b) Upon presentation of Department
			 credentials, inspectors of the Department shall be permitted access to inspect
			 all physical facilities and records of the program and to make inquiries of
			 program staff and clients.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2090 - SUBACUTE ALCOHOLISM AND SUBSTANCE ABUSE TREATMENT SERVICES › Section 2090.100 - Sanctions for Non-Compliance/Audits

Current through Register Vol. 48, No. 28, July 12, 2024
a) Failure to comply with the requirements of
			 this Part shall result in the provider being issued a written warning or having
			 its certification suspended or terminated for the Illinois Medical Assistance
			 Program.
b) The Department shall
			 issue written notification to a certified provider who has failed to comply
			 with any provision specified in this Part. The provider shall have a maximum of
			 60 calendar days from the date of the written notice to correct the cited
			 deficiencies. However, such action shall not preclude the Department from
			 initiating proceedings as specified in subsection (g) of this
			 Section.
c) The Department may also
			 conduct post-payment audits based on volume of billings, complaints, identified
			 deficiencies or non-compliance with this Part, or pursuant to a random
			 selection process as necessary to monitor for compliance with this
			 Part.
d) The Department shall audit
			 a statistically significant randomly selected sampling of client records at the
			 audited program.
e) The Department
			 shall follow the recoupment formula approved by the Department of Public Aid,
			 should the audit result in recoupment.
f) Upon completion of the post-payment audit
			 the Department shall submit written notification to the program regarding audit
			 findings and amounts determined to be recoupable. The program shall respond to
			 the notification within 15 days with supporting documentation regarding the
			 recoupment amount. If such documentation proves that the recoupment amount is
			 inaccurate, the amount shall be revised. The program may also request a 100%
			 audit. The department may reduce future payments at a percentage per month or
			 in a lump sum, or demand repayment in a lump sum.
g) The Department and the Department of
			 Public Aid shall jointly initiate administrative proceedings pursuant to 89
			 Ill. Adm. Code
			 140.16
			 to suspend or terminate certification and eligibility to participate in the
			 Illinois Medical Assistance Program for reasons set forth in 89 Ill. Adm. Code
			 140.16
			 or for failing to comply with any provision of this Part. The Department may
			 also initiate administrative proceedings pursuant to 89 Ill. Adm. Code
			 140.15
			 to recover money. Both types of proceedings shall be conducted under 89 Ill.
			 Adm. Code 104: Subpart C (Rules of Practice for Medical Vendor
			 Hearings).
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2110 - PERINATAL MENTAL HEALTH DISORDERS PREVENTION AND TREATMENT › Section 2110.10 - General Applicability

Current through Register Vol. 48, No. 28, July 12, 2024
This Part implements the Perinatal Mental Health Disorders
				Prevention and Treatment Act [405 ILCS 95 ] that concerns perinatal mental
				health disorders, commonly referred to as "post-partum
				depression".
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2110 - PERINATAL MENTAL HEALTH DISORDERS PREVENTION AND TREATMENT › Section 2110.20 - Purpose

Current through Register Vol. 48, No. 28, July 12, 2024
The purpose of the Perinatal Mental Health Disorders Prevention
				and Treatment Act and this Part is to provide information to women and their
				families about perinatal mental health disorders in order to lower the
				likelihood that new mothers will continue to suffer from this illness in
				silence; to develop procedures for screening for risk of perinatal mental
				health disorders and assessing women for perinatal mental health disorders
				during prenatal and postnatal visits to licensed health care professionals; to
				promote early detection and early treatment of perinatal mental health
				disorders; and, when medically appropriate, to avoid
				medication.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2110 - PERINATAL MENTAL HEALTH DISORDERS PREVENTION AND TREATMENT › Section 2110.30 - Incorporation by Reference

Current through Register Vol. 48, No. 28, July 12, 2024
Clinical Report Incorporating Recognition and Management of
				Perinatal and Postpartum Depression into Pediatric Practice, Marian F. Earls
				and The Committee on Psychosocial Aspects of Child and Family Health,
				Pediatrics, published online October 25, 2010, available at
www.pediatrics.org
.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2110 - PERINATAL MENTAL HEALTH DISORDERS PREVENTION AND TREATMENT › Section 2110.40 - Definitions

Current through Register Vol. 48, No. 28, July 12, 2024
"DHS" means the Department of Human Services.
"HFS" means the Department of Healthcare and Family
				Services.
"Hospital" has the meaning given to that term in the Hospital
				Licensing Act [210 ILCS 85/3 ].
"Licensed health care professional" means a physician licensed
				to practice medicine in all its branches, an advanced practice nurse who has a
				collaborative agreement with a collaborating physician that authorizes care, or
				a physician assistant who has been delegated authority to provide care. A
				medical director within a public health setting may assign the task of
				screening to a subordinate, under his/her supervision, who has satisfactorily
				completed training on perinatal mental health disorders and use of screening
				tools.
"Perinatal mental health disorders", commonly referred to as
				"post-partum depression", means a wide range of emotional, psychological and
				physiological reactions to childbirth, including feelings of hopelessness,
				excessive guilt, sustained sadness, and thoughts of death or suicide, that
				challenge the stamina of a woman during pregnancy and after childbirth and
				impair her ability to care for her child.
"Postnatal care" means an office visit to a licensed health
				care professional occurring after birth, with reference to the infant or
				mother.
"Prenatal care" means an office visit to a licensed health care
				professional for pregnancy-related care occurring before birth.
"Screening" means the use of a questionnaire as a tool
				administered by a licensed health care professional to detect perinatal mental
				health disorders, such as the Edinburg Postnatal Depression Scale, the
				Postpartum Depression Screening Scale, the Beck Depression Inventory, the
				Patient Health Questionnaire, or other validated assessment methods, including
				any validated screening tool approved by HFS to detect perinatal mental health
				disorders.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2110 - PERINATAL MENTAL HEALTH DISORDERS PREVENTION AND TREATMENT › Section 2110.50 - Prenatal Visits

Current through Register Vol. 48, No. 28, July 12, 2024
A licensed health care professional providing prenatal care to
				a woman at a prenatal visit shall:
a)
			 Once during the pregnancy, provide education regarding the signs and symptoms
			 of perinatal mental health disorders, including but not limited to offering
			 materials to the patient, and if possible, to fathers, partners and other
			 family members.
b) Once during the
			 pregnancy, request permission from the pregnant patient to offer education
			 regarding perinatal mental health disorders to fathers, partners and other
			 family members.
c) Invite the
			 pregnant patient, at least once during the pregnancy, to complete a perinatal
			 mental health disorders questionnaire unless the patient states that she has
			 already completed such a questionnaire during the current pregnancy. The
			 questionnaire must be offered more frequently when, in the professional
			 judgment of the licensed health care professional, a reasonable possibility
			 exists that the woman suffers from perinatal mental health disorders.
d) Repeat the questionnaire for perinatal
			 mental health disorders when, in the professional judgment of the licensed
			 health care professional, a reasonable possibility exists that the woman
			 suffers from perinatal mental health disorders.
e) Review the completed questionnaire in
			 accordance with the formal opinions and recommendations of the American
			 Congress of Obstetricians and Gynecologists. Information and materials may be
			 found at
www.acog.org
., with respect to
			 perinatal mental health disorders. The ACOG Depression Toolkit may be found at
			 http://mail.ny.acog.org/website/DepressionToolkit.pdf [File Link Not
			 Available].
f) Document the offer
			 of the questionnaire in the patient record.
g) Obtain the patient's consent to share the
			 results of the questionnaire with the patient's primary licensed healthcare
			 professional, if indicated by criteria commonly relied upon by providers in
			 assessing a patient's mental health. If the patient is determined to present an
			 acute danger to herself or someone else, consent is not required.
h) Document action taken if the questionnaire
			 indicates that the woman is experiencing symptoms of perinatal mental health
			 disorders.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2110 - PERINATAL MENTAL HEALTH DISORDERS PREVENTION AND TREATMENT › Section 2110.60 - Hospital Maternity Care Services

Current through Register Vol. 48, No. 28, July 12, 2024
a) Hospitals that provide labor and delivery
			 services shall:
1) Provide complete
			 information about perinatal mental health disorders, including its symptoms,
			 methods of coping with the illness, and treatment resources to patients who
			 have given birth, prior to discharge from the maternity unit following
			 childbirth. Hospitals may use written information provided by DHS to satisfy
			 this requirement.
2) If possible,
			 provide the written information to fathers, partners and other family
			 members.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2110 - PERINATAL MENTAL HEALTH DISORDERS PREVENTION AND TREATMENT › Section 2110.70 - Postnatal Visits

Current through Register Vol. 48, No. 28, July 12, 2024
A licensed health care professional providing primary care,
				obstetric or gynecological services to a woman at a postnatal visit
				shall:
a) Invite a post-partum patient
			 to complete a questionnaire to screen for risk of perinatal mental health
			 disorders at least once post-partum.
b) Offer the questionnaire at least once
			 post-partum, unless the woman states that she has already completed the
			 questionnaire during this period. The questionnaire may be offered more
			 frequently, based on the licensed health care professional's clinical judgment.
			 In deciding on the timing or frequency of any additional screenings, the
			 licensed healthcare professional may consider the recommendations of the
			 American Academy of Pediatrics Clinical Report Incorporating Recognition and
			 Management of Perinatal and Postpartum Depression into Pediatric Practice (AAP
			 in Journal of Pediatrics in 2010 126:5; pgs. 1032-1039).
c) Review the completed questionnaire in
			 accordance with the formal opinions and recommendations of the American College
			 of Obstetricians and Gynecologists, found at
www.acog.org
., with respect to perinatal mental
			 health disorders. The ACOG Perinatal Depression Toolkit may be found at
			 http://mail.ny.acog.org/website/DepressionToolkit.pdf [File Link Not
			 Available].
d) Document the offer
			 of the questionnaire in the patient record.
e) Obtain the patient's consent to share the
			 results of the questionnaire with the patient's primary licensed healthcare
			 professional, if indicated. If the patient is determined to present an acute
			 danger to herself or someone else, consent is not required.
f) Document actions taken if the
			 questionnaire indicates that the woman is experiencing symptoms of perinatal
			 mental health disorders.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2110 - PERINATAL MENTAL HEALTH DISORDERS PREVENTION AND TREATMENT › Section 2110.80 - Visits to Pediatric Providers

Current through Register Vol. 48, No. 28, July 12, 2024
Licensed health care professionals providing pediatric care to
				an infant shall:
a) Invite the infant's
			 mother to complete a questionnaire at least once 6 weeks post-delivery to
			 screen for risk of perinatal mental health disorder. This should occur prior to
			 the infant's first birthday, unless the mother states that she has already
			 completed the questionnaire during the post-partum period. The questionnaire
			 may be offered earlier or more frequently, based on the licensed health care
			 professional's clinical judgment. In deciding on the timing or frequency of any
			 additional screenings, the licensed health care professional may consider the
			 recommendations of the American Academy of Pediatrics Clinical Report
			 Incorporating Recognition and Management of Perinatal and Postpartum Depression
			 into Pediatric Practice found at
http://www.pediatrics.org
.
b) Review the completed questionnaire in
			 accordance with the formal opinions and recommendations of the American Academy
			 of Pediatrics or the American College of Obstetricians and Gynecologists, found
			 at
www.acog.org
., with respect to perinatal
			 mental health disorders.
c)
			 Document the offer of the questionnaire to the mother in the infant's or the
			 mother's record, if available.
d)
			 Obtain the mother's consent to share the results of the questionnaire with the
			 mother's primary licensed healthcare professional, if indicated. If the mother
			 is determined to present an acute danger to herself or someone else, consent is
			 not required.
e) Document actions
			 taken if the questionnaire indicates that the woman is experiencing symptoms of
			 perinatal mental health disorders.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2110 - PERINATAL MENTAL HEALTH DISORDERS PREVENTION AND TREATMENT › Section 2110.90 - Questionnaire Tool

Current through Register Vol. 48, No. 28, July 12, 2024
The perinatal mental health disorders questionnaire utilized
				must be approved by HFS. Approved tools used for screening pregnant and
				post-partum women for perinatal mental health disorders can be found in the
				Provider Handbook at
www2.illinois.gov/hfs/medicalprovider/maternalandchildhealthpromotion
.
				HFS, in coordination with DHS, will notify providers of changes to the list of
				approved tools.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2110 - PERINATAL MENTAL HEALTH DISORDERS PREVENTION AND TREATMENT › Section 2110.100 - Privacy of Questionnaire Results

Current through Register Vol. 48, No. 28, July 12, 2024
Documentation concerning issues of mental health are protected
				in accordance with the Confidentiality of Alcohol and Drug Abuse Patient
				Records Rules ( 42 CFR 2 ) and the Mental Health and Developmental Disabilities
				Confidentiality Act [740 ILCS 110 ] and shall be shared only with the written
				consent of the patient, except as provided in Section
				2110.80(d).
				If the licensed health care professional's patient is the infant, he/she shall
				request permission to share screening results with the woman's primary health
				care provider, except as provided in Section
				2110.80(d).
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2110 - PERINATAL MENTAL HEALTH DISORDERS PREVENTION AND TREATMENT › Section 2110.110 - Follow-Up

Current through Register Vol. 48, No. 28, July 12, 2024
a) If screening
			 results or clinical judgment indicate a need for follow-up, pre-natal and
			 post-natal licensed health care professionals may, in accordance with their
			 professional judgment, offer referral to an appropriate healthcare provider for
			 further assessment and/or treatment.
b) If screening results or clinical judgment
			 indicate a need for follow-up, pediatric care licensed health care
			 professionals whose patient is the infant may, in accordance with their
			 professional judgment, offer referral to an appropriate healthcare provider for
			 further assessment and/or treatment.
c) Licensed health care professionals
			 treating patients who demonstrate risk of immediate harm to self or others
			 shall notify emergency personnel or follow existing emergency protocols of the
			 health care setting.
Illinois Administrative Code › Title 77 - PUBLIC HEALTH › Part 2250 - ILLINOIS AMERICORPS PROGRAM › Section 2250.10 - Purpose and Summary

Current through Register Vol. 48, No. 28, July 12, 2024
The purpose of this Part is to provide for the implementation
				and administration of AmeriCorps, a national service program created by the
				National and Community Service Trust Act of 1993, within the Illinois
				Department of Human Services and the Illinois Commission on Volunteerism and
				Community Service, also referred to as the Serve Illinois Commission.
				AmeriCorps is a federal program implemented by the states designed to address
				the nation's educational, public safety, human and environmental needs by
				providing an opportunity for people, 18 years of age or older, to serve their
				communities in programs and, in return, receive a stipend and an educational
				award that can be used to repay student loans or for future
				education.